| Literature DB >> 23087801 |
Kemal Behzatoğlu1, Pelin Yildiz, Meltem Oznur, Erol R Bozkurt.
Abstract
Abundant myxoid stroma rarely occurs in urothelial carcinomas, and may cause diagnostic challenges when cells with eosinophilic cytoplasm forming nests and cords in a myxoid background are seen, particularly in the absence of typical carcinomatous appearance. Microscopic examination of transurethral resection specimen of a 71-year-old male patient revealed non-cohesive oval or elongated tumor cells with eosinophilic cytoplasm arranged in cord-like filigree pattern in an abundant myxoid stroma. Immunohistochemically the tumor was positive for cytokeratin 7, cytokeratin 20, and 34BE12. About 90 to 100% nuclear staining was observed with p63, p53, and Ki-67. A second neoplasm with a flat overlying urothelial epithelium and a complete inverted cellular growth pattern was also noted. The neoplasm exhibited less than 2% and 10% nuclear staining with Ki-67 and p53, respectively. Considering histological, histochemical, and immunohistochemical findings, a diagnosis of synchronous urothelial carcinoma with abundant myxoid stroma and inverted papilloma was made.Entities:
Keywords: inverted papilloma.; myxoid; transitional cell carcinoma; urinary bladder; urothelial carcinoma
Year: 2012 PMID: 23087801 PMCID: PMC3475952 DOI: 10.4081/rt.2012.e45
Source DB: PubMed Journal: Rare Tumors ISSN: 2036-3605
Figure 1The low magnification, demonstrates abondant myxoid stroma with cord-like and individual tumor cells.
Figure 2The high magnification, urothelial carcinoma composed of individual cells anf irregular agregates associated with myxoid stroma.
Figure 3The high magnification, inverted urothelial papilloma and carcinomas mass.
Figure 4The high magnification, inverted urothelial papilloma and carcinomas mass.
Figure 5Alcian blue positivity in the stroma.
Figure 6Urothelial carcinoma with abondant myxoid stroma diffuse nuclear p63 immunoreactivity.
Figure 7Urothelial carcinoma with abondant myxoid stroma diffuse cytoplasmic cytokeratin 34BE12 immunoreactivity.